Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (Diluted Average) (2020 - 2025)

Enanta Pharmaceuticals filings provide 8 years of Shares Outstanding (Diluted Average) readings, the most recent being $28.7 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 35.36% to $28.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.7 million, a 35.36% increase, with the full-year FY2025 number at $21336.0, up 0.85% from a year prior.
  • Shares Outstanding (Diluted Average) hit $28.7 million in Q4 2025 for Enanta Pharmaceuticals, up from $21336.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $28.7 million in Q4 2025 to a low of $20171.0 in Q3 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $20.8 million (2022), compared with a mean of $15.6 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 0.6% in 2024 and later surged 35.36% in 2025.
  • Enanta Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $20.4 million in 2021, then rose by 2.1% to $20.8 million in 2022, then increased by 1.31% to $21.1 million in 2023, then grew by 0.71% to $21.2 million in 2024, then skyrocketed by 35.36% to $28.7 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $28.7 million (Q4 2025), $21336.0 (Q3 2025), and $21.4 million (Q2 2025) per Business Quant data.